[HTML][HTML] The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
Pre-existing cross-reactive immune responses to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) proteins in infection-naive subjects have been described by …
coronavirus 2 (SARS-CoV-2) proteins in infection-naive subjects have been described by …
[HTML][HTML] Is cross-reactive immunity triggering COVID-19 immunopathogenesis?
A Beretta, M Cranage, D Zipeto - Frontiers in immunology, 2020 - frontiersin.org
The serological responses to both SARS-CoV-1 and SARS-CoV-2 virus have some unique
characteristics that suggest cross-reactive priming by other human coronaviruses (hCoVs) …
characteristics that suggest cross-reactive priming by other human coronaviruses (hCoVs) …
[HTML][HTML] Characterization of SARS-CoV-2-Specific humoral and cellular immune responses induced by inactivated COVID-19 vaccines in a real-world setting
Z Li, T Xiang, B Liang, H Deng, H Wang… - Frontiers in …, 2021 - frontiersin.org
While the immunogenicity of inactivated vaccines against coronavirus disease 2019 (COVID‐
19) has been characterized in several well-conducted clinical trials, real-world evidence …
19) has been characterized in several well-conducted clinical trials, real-world evidence …
[HTML][HTML] Cross-protective immunity following coronavirus vaccination and coronavirus infection
Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have
shown efficacy against SARS-CoV-2, it is unknown if coronavirus vaccines can also protect …
shown efficacy against SARS-CoV-2, it is unknown if coronavirus vaccines can also protect …
[HTML][HTML] Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination
SARS-CoV-2 is a novel betacoronavirus that caused coronavirus disease 2019 and has
resulted in millions of deaths worldwide. Novel coronavirus infections in humans have …
resulted in millions of deaths worldwide. Novel coronavirus infections in humans have …
[HTML][HTML] Lessons for COVID-19 immunity from other coronavirus infections
A Sariol, S Perlman - Immunity, 2020 - cell.com
A key goal to controlling coronavirus disease 2019 (COVID-19) is developing an effective
vaccine. Development of a vaccine requires knowledge of what constitutes a protective …
vaccine. Development of a vaccine requires knowledge of what constitutes a protective …
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
M Grobben, K van der Straten, PJM Brouwer… - Elife, 2021 - elifesciences.org
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …
[HTML][HTML] Antibody responses to natural SARS-CoV-2 infection or after COVID-19 vaccination
H Altawalah - Vaccines, 2021 - mdpi.com
The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is
the causative agent of the ongoing pandemic of coronavirus disease 2019 (COVID-19). The …
the causative agent of the ongoing pandemic of coronavirus disease 2019 (COVID-19). The …
[HTML][HTML] Immunity to SARS-CoV-2: lessons learned
J Fergie, A Srivastava - Frontiers in immunology, 2021 - frontiersin.org
In the year since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) and with understanding of the etiology of the coronavirus disease 2019 (COVID-19) …
CoV-2) and with understanding of the etiology of the coronavirus disease 2019 (COVID-19) …
[HTML][HTML] Will SARS-CoV-2 variants of concern affect the promise of vaccines?
RK Gupta - Nature Reviews Immunology, 2021 - nature.com
Initial optimism regarding the development of COVID-19 vaccines has been tempered by the
emergence of new variants of SARS-CoV-2. Will vaccination be able to contain the …
emergence of new variants of SARS-CoV-2. Will vaccination be able to contain the …